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Abstract
Over the last century, eosinophils have been regarded ambiguously either as ‘friends’ 
or ‘foes’. Recent developments have greatly enhanced our understanding of the role 
and function of eosinophils in health and disease. Pathogenic eosinophilic inflam-
mation can lead to severe diseases in various organs, such as the gastrointestinal 
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1 |  INTRODUCTION
Eosinophilic granulocytes are among the most distinctive cells 
in human blood, mainly due to the bright colour given by eosin, 
an aniline dye first used in 1877 by Paul Ehrlich1 for the differ-
entiation of white blood cells. In subsequent decades, there was 
marked controversy over whether these cells could be regarded 
as ‘good’ or ‘bad’,2 and lately there has been marked progress 
and increasing interest in these cells. Therefore, the German 
Society of Allergology and Clinical Immunology (DGAKI) 
organized a ‘Focus’ workshop to reflect the state of the art in 
this field and discuss practical aspects of management of eo-
sinophilic diseases. Here, we summarize the outcomes of this 
forum, focussing on current developments, and discuss clinical 
and experimental research of note in the field of eosinophil 
granulocytes and eosinophil- related diseases.
2 |  BIOLOGY OF EOSINOPHILS
The pro- inflammatory effects of eosinophils, exerted through 
release of toxic mediators, cytokines and other products and 
causing symptoms of allergic disorders (Figure  1), have 
generated much attention. However, eosinophils have many 
physiological functions.3,4 Eosinophils are a major cell pop-
ulation of the gastrointestinal (GI) tract, and their homing to 
the lamina propria is independent of inflammation. Indeed, 
the first eosinophils appear in the GI tract already during foe-
tal development, long before the gut is colonized by the mi-
crobiota. The development of normal- sized Peyer´s patches 
in the GI tract requires eosinophils, and in their absence, IgA 
class switching is impaired.5 Consequently, intestinal and 
serum IgA is significantly reduced in eosinophil- deficient 
mice. Furthermore, eosinophils play a crucial role in im-
mune homeostasis, as they control T cell responses to en-
vironmental antigens in mucosal tissues of the lung and 
the GI tract,6 and prevent inflammatory reactions induced 
by infections with natural parasites, such as the bacterium 
Helicobacter pylori.7 Eosinophils also have an essential role 
in long- term immune protection. In the bone marrow, they 
provide the cytokine APRIL, which promotes plasma cell 
longevity.8 Furthermore, eosinophils play an important role 
during puberty,9 in the structural development of adipose 
tissue, and in tumour and transplant rejection.2 Although 
hypereosinophilia in relation to tumours was first described 
more than 120 years ago, its role in tumours is still unde-
fined.10 Eosinophils release antitumorigenic (eg TNF- α, cati-
onic proteins and IL- 18) and protumorigenic molecules (eg 
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tract, airways, heart and skin. In a 2- day focus workshop of the German Society 
for Allergology and Clinical Immunology (DGAKI), the state of the art was dis-
cussed and practical recommendations for diagnosis and treatment of eosinophilic 
diseases, with a particular focus on new biologics, such as anti- interleukin 5 and anti- 
interleukin 5R, were derived.
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pro- angiogenetic factors) depending on the tumour microen-
vironment.11,12 In several neoplasias (eg melanoma, gastric, 
colorectal, oral and prostate cancer), eosinophilia was related 
to a better outcome, whereas in others, such as Hodgkin's 
lymphoma, eosinophilia has been linked to poor progno-
sis.12,13 A better understanding of the paradoxical role in 
cancer progression could help design therapeutic strategies.
Eosinophils are components in adipose tissue infiltrates and 
promote glucose homeostasis.14 Mesenchyme- derived stromal 
cells in white adipose tissue activate resident type 2 innate 
lymphoid cells (ILC2) to release IL- 5.15 IL- 5 activated eosin-
ophils release IL- 4, which, together with ILC2 released IL- 13, 
induces the conversion of resident tissue macrophages to acti-
vated macrophages able to release norepinephrine- stimulating 
adipose browning.16,17 Eosinophil- deficient mice developed 
weight gain and glucose intolerance whereas hypereosinophilic 
mice displayed neither weight gain and nor glucose intolerance 
when fed a high- calorie diet.14 However, recent data suggest 
that elevating adipose eosinophils in obese mice by IL- 5 did 
not rescue metabolic impairments.18 Further research needs to 
clarify these findings. Transgenic mouse models have allowed 
new understanding of eosinophil functions. The IL- 4eGFP re-
porter mice were used to identify eosinophil- committed pre-
cursor cells in the foetal liver where they express low levels of 
Siglec- F, and no CCR3.19 In adult mice, resting and activated 
eosinophils can be distinguished by expression of CD62L, 
Siglec- F, Pir- B and CD29 on the cell surface.19
Corresponding functional studies have provided new in-
sights into the physiology of eosinophils. Interestingly, anal-
ysis of eosinophil turnover by means of BrdU incorporation 
assays has revealed that helminth- induced tissue eosinophilia 
was caused by recruitment of already existing eosinophils, 
rather than that of de novo- generated eosinophils from the bone 
marrow.20 Mice with eosinophil- specific expression of the Cre 
recombinase have demonstrated an important role of the NF- 
kappa B pathway for regulation of eosinophilia after helminth 
infection.21 Furthermore, the alarmin IL- 33 can promote sur-
vival of eosinophils by autocrine GM- CSF signalling.22
Eosinophils are often found together with mast cells 
(MCs), not only in allergy conditions, but also in other dis-
eases, such as mastocytosis, systemic lupus erythematosus, 
bullous pemphigoid (BP), scleroderma, chronic graft- versus- 
host disease, cancers, atherosclerosis and idiopathic hyper-
eosinophilic syndrome (HES). A type of pro- inflammatory 
cross- talk, called ‘Allergic Effector Unit’, with CD48 and 
2B4 at the core, results in increased eosinophil chemotaxis, 
survival, degranulation, cytokine production and MC sur-
vival (Figure 2).23- 28 This cross- talk also involves inhibitory 
receptors, that is, CD300a and Siglec- 7 or Siglec 8, on MCs 
and eosinophils.25 Specific monoclonal antibodies blocking 
CD48 and activating CD300a and Siglec- 7 or Siglec 8 could 
thus serve as potential drugs in future.
The activation of eosinophils results in several func-
tional responses, including the release of granule proteins. 
However, control of the toxicity of these granule proteins 
within the eosinophil itself has not yet been identified. 
Recently, studies involving a combination of dye/immu-
nostaining, immuno- transmission electron microscopy 
and X- ray micro- crystallography have indicated that eo-
sinophil major basic protein (MBP), a protein at the core 
of specific granules, is enclosed by a crystal lattice with 
amyloid- like properties, enabling the inert storage of the 
otherwise toxic protein.29 Following eosinophil activa-
tion, MBP is mobilized, unpacked and released as non- 
toxic oligomers. Upon secretion, an aggregation process is 
initiated, resulting in the generation of toxic MBP that is 
able to exert its microbiocidal effects. Interestingly, larger 
extracellular non- toxic MBP aggregates can be detected 
in eosinophilic tissues, which may explain how tissue de-
struction by MBP can be limited. These data indicate that 
the toxicity of eosinophil MBP is controlled by functional 
amyloid formation.29
Granule proteins can also occur in the extracellular space, 
in association with so- called ‘eosinophil extracellular traps’ 
(EETs).30 Eosinophil activation initiates the formation of EETs, 
consisting of catapult- like release of mitochondrial DNA and 
F I G U R E  1  Examples of eosinophilic 
mediators and receptors involved in allergic 
inflammation
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granule proteins that form structures able to bind and kill bacte-
ria. Thymic stromal lymphopoietin (TSLP) and Staphylococcus 
aureus serve as strong stimuli for EET generation in the con-
text of eosinophil adhesion.31 Evidence that mitochondrial as 
well as nuclear DNA is released from eosinophils by an active 
process was obtained from live- cell imaging analyses.30- 32 As a 
component of the innate immune response, EETs were detected 
in several allergic, infectious and autoimmune eosinophilic dis-
eases,31 including bronchial asthma, atopic dermatitis (AD),33,34 
eosinophilic esophagitis and chronic rhinosinusitis.35,36
Recently, it has been proposed that eosinophil cytolysis is 
a manifestation of regulated necrosis, since the death process 
depends on receptor- interacting protein kinase 3 (RIPK3) and 
mixed lineage kinase- like (MLKL) protein.37 Notably, previ-
ous pharmacological activation of autophagy inhibits eosino-
phil cytolysis. Thus, suppressing the RIPK3- MLKL pathway 
and stimulating autophagy in eosinophils may represent new 
therapeutic strategies to prevent eosinophil- mediated tissue 
damage.
3 |  EOSINOPHILIC DISEASES
Eosinophilic inflammation occurs in various diseases,38 
mostly allergic and parasitic diseases, but also in autoim-
mune diseases, in the course of malignancies (eg lymphoma), 
conditions induced by drugs (eg acetylsalicylic acid, cefoxi-
tin, penicillin), and rare conditions, such as HES.39
3.1 | Eosinophilic skin diseases
Eosinophilic inflammation is a characteristic of many skin 
diseases of allergic, infectious, haematologic, autoimmune or 
vascular origin (Table 1). There are some particular condi-
tions in which eosinophilic inflammation is idiopathic, such 
as episodic angioedema,40 eosinophilic cellulitis (Well's syn-
drome), eosinophilic fasciitis, granuloma faciale, angiolym-
phoid hyperplasia with eosinophilia,41 eosinophilic folliculitis 
(Ofuji syndrome), as well as in the context of hypereosino-
philia (HE) or HES.42,43 IgG4- related diseases and drug re-
actions with eosinophilia and systemic symptoms (DRESS) 
are multisystem diseases with strong eosinophilic inflamma-
tion in the skin.44 The first successful use of the anti- IL- 5 
monoclonal antibody mepolizumab was demonstrated in 
HES with skin involvement.42 AD, a type 2 cytokine- driven 
F I G U R E  2  Examples of eosinophil- 
mast cell interactions with effects on allergic 
inflammation
T A B L E  1  Diseases involving eosinophilic inflammation of the 
skin
Type Disease
Allergies Eczema (atopic dermatitis)
Urticaria, angioedema
Drug reactions (eg, DRESS)








Vascular Eosinophilic granulomatosis with 
polyangiitis (Churg- Strauss syndrome)
Haematological 
Idiopathic
Hypereosinophilic syndromes (myeloid 
variant)
Eosinophilic cellulitis (Well's syndrome)
Episodic angioedema with eosinophilia 
(Gleich syndrome)
Granuloma faciale
Angiolymphomatoid hyperplasia with 
eosinophilia
Hypereosinophilic syndrome
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inflammatory skin disease, is associated with increased eo-
sinophil numbers both in blood and skin, and with elevated 
serum and urine levels of eosinophilic secretion products.45 
A clinical trial investigated anti- IL- 5, which target the major 
T- cell- derived eosinophilic growth and survival factor, for 
treatment of AD.46 In this small proof- of- concept trial, the 
primary study endpoint of clear improvement of AD was not 
reached, but some individual parameters showed promise. A 
recently published placebo- controlled study indicated the ef-
ficacy of mepolizumab in patients with moderate to severe 
AD, demonstrating the improvement of clinical scores in 
patients treated with subcutaneously administered mepoli-
zumab.47 Thus, future studies with anti- IL- 5 or anti- IL- 5R 
may yield additional positive results.
The role of eosinophils has been studied in bullous au-
toimmune dermatoses, such as pemphigus (involving auto- 
antibodies against desmosomal proteins) and pemphigoid 
(involving auto- antibodies against adhesion proteins).48 In 
the pre- bullous stage of pemphigus, eosinophils infiltrate the 
epidermis, known as eosinophilic spongiosis. Desmoglein- 
induced secretion of IL- 4, - 5 and - 13- positive CD4 + T cells 
may attract eosinophils via IL- 5.48
In BP, which has a higher prevalence in the elderly pop-
ulation, blisters are filled with an eosinophil- rich leukocyte 
infiltrate, with strongly enhanced activation of eosinophils, in-
cluding those in the circulation.49 Eosinophils can also release 
mitochondrial DNA together with granule proteins (EETs) 
in proximity to apoptotic keratinocytes in BP patients.34,50 
Moreover, IL- 5- activated eosinophils potentially contribute 
to blister formation by directly causing dermal- epidermal 
separation.50 Eosinophils in BP also produce high levels of 
IL- 31,51 which may be involved in the strong itching sensa-
tion. Studies with the anti- IL- 5 antibody mepolizumab have 
demonstrated efficacy for the treatment of hypereosinophilic 
diseases. The primary endpoint was the improvement of clin-
ical symptoms, decrease in the blood eosinophil count and re-
duction of the prednisone dose to 10 mg or less per day for 8 
or more consecutive weeks.52 Recently, a study indicated the 
efficacy of treatment with an anti- eotaxin- 1 monoclonal anti-
body (bertilimumab) in BP and demonstrated an 81% decline 
in the subjects' BP Disease Area Index. The primary endpoint 
was safety, including the incidence of adverse effects.53,54
3.2 | Eosinophils in upper airway diseases
Chronic rhinosinusitis (CRS) is often considered an ‘eosino-
philic’ upper airway inflammatory disease; however, there 
are several degrees of eosinophil involvement, recently de-
scribed as non- type 2, moderate type 2 and severe type 2 in-
flammation, ranging from CRS without to CRS with massive 
nasal polyps and comorbid asthma.55 The risk for and the 
severity of type 2 inflammation in CRS can vary consider-
ably depending on the patient's place of residence (eg Asia 
vs. Europe) and may furthermore increase over time at places 
with low incidence.56 A possible role of Staphylococcus au-
reus has been discussed via release of enterotoxins SEA- SEE 
and TSST- 1, or serine- protease- like proteins.57,58 Serine- 
protease- like proteins can elicit IgE antibody responses in 
asthmatic patients and induce Th2 responses.57 Repeated in-
tratracheal applications of SplD induced allergic asthma in 
C57BL/6 J mice and led to IL- 33 and eotaxin production, 
eosinophilia, bronchial hyperreactivity and goblet cell hyper-
plasia.58 Blocking IL- 33 activity with a soluble ST2 receptor 
consequently decreased lung eosinophils, innate lymphoid 
cells and T cells, as well as IL- 5 and IL- 13 production in 
lymph nodes, which resembled superantigen activities.57 
Furthermore, in nasal polyp tissue samples, EET formation 
was observed.36 The understanding of eosinophil- associated 
endotypes is likely to lead to new differentiated approaches 
in the management of CRS.59,60
3.3 | Eosinophils in lung diseases
In the clinical classification of eosinophilic lung disease, it is 
important to determine whether the disorder is limited to the 
lung or reflects a multisystemic disease. Lung- limited eosin-
ophilic diseases include eosinophilic pneumonia,61 parasite 
infection or eosinophilic airway diseases, such as asthma or al-
lergic broncho- pulmonary aspergillosis. Classical multisystem 
eosinophilic diseases include eosinophilic granulomatosis and 
polyangiitis (eGPA),62,63 drug reactions with eosinophilia and 
HES. Eosinophils are increased in atopic as well as in non- atopic 
asthma.40 In patients with asthma, treatment is guided by the 
absolute numbers of eosinophils in the blood,64 particularly in 
patients with severe eosinophilic asthma, where treatment with 
either IL- 5 or IL- 5Rc antibodies results in marked improve-
ment,65,66 even in systemic steroid- dependent patients.67,68 
Interestingly, in other lung diseases, such as eGPA,69 anti- IL- 5 
treatment resulted in about 40% remission rates.70 Clinical stud-
ies with IL- 5 blockade are warranted for eosinophilic pneumo-
nia or allergic broncho- pulmonary aspergillosis.69,70
3.4 | Eosinophilic gastrointestinal diseases
Eosinophilic esophagitis (EoE) has increased in prevalence 
both in adults and in children since its first description in 
the 90s.71,72 Diagnostic criteria include oesophageal steno-
sis with dysphagia and symptoms not otherwise explained, 
together with tissue eosinophilia (>15 eosinophils per high- 
power field). The factors responsible for EoE range from 
environmental factors, including food allergens and the 
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microbiome, interacting with the oesophageal epithelium 
with consecutive release of atopy- enhancing cytokines, 
to genetic factors such as gender and genetic variants.73 
A recent review revealed a delay of several years between 
symptom onset and diagnosis increasing the risk for fibro-
stenosis.74 Moreover, relatively high recurrence rates and 
low rates of spontaneous recovery were described, which 
indicate that EoE is a disorder persisting from childhood to 
adulthood.74
The majority of children with atopy have comorbid 
asthma, allergic rhinitis and/or atopic eczema (‘asthma of 
the oesophagus’). There is a broad overlap between eosin-
ophilic esophagitis (EoE) and IgE- mediated food allergies, 
particularly against cow's milk, beef, chicken, peanuts, 
chicken eggs, wheat and soy.75 Therefore, a critical eval-
uation of the relevance of specific IgE levels or skin tests 
against food proteins is crucial in the diagnostic work- up, 
in addition to endoscopy with biopsy. The response to first- 
line therapy with proton pump inhibitors (PPI) defines the 
new subtypes of eosinophilic GI diseases, namely PPI- 
unresponsive and often IgE- associated EoE versus PPI- 
responsive oesophageal eosinophilia.76 However, it has 
been suggested that PPI responsiveness is not part of a di-
agnostic criteria but rather an effective treatment for some 
patients.73,77,78 Less is known about eosinophilic inflam-
mation of other parts of the GI tract, such as eosinophil 
gastroenteritis, which are often associated with symptoms 
of irritable bowel syndrome.
3.5 | Hypereosinophilia and 
hypereosinophilic syndrome
Over the past two decades, understanding of HE and HE- 
induced organ damage has increased substantially.79- 81 
Neoplastic and reactive disorders underlying HE can be 
distinguished, and several proposals for the classifica-
tion of HE- related syndromes have been developed.81- 83 
Certain myeloid neoplasms and various reactive condi-
tions are frequently associated with HE, but HE may also 
be seen with no apparent underlying disease (idiopathic 
HE).82,83 In myeloid neoplasms, eosinophils are consid-
ered to belong to the malignant clone, whereas in reactive 
conditions, eosinophilia is usually a reactive process trig-
gered by eosinophilopoietic cytokines. HE- related organ 
damage, also known as HES, is seen in patients with hae-
matologic malignancies, but also in reactive conditions.83 
When no underlying disease is detected, the diagnosis 
is idiopathic HES.83 In patients with clonal HE (with or 
without HES), several different molecular markers can 
be detected, such as fusion genes involving PDGFRA (eg 
FIP1L1- PDGFRA), PDGFRB, FGFR1, ABL1 or JAK2 (eg 
PCM1- JAK2).83
4 |  MANAGEMENT AND NOVEL 
AND EXPERIMENTAL THERAPIES
Type- 2 inflammation is the predominant pattern in eosino-
philic diseases. Eosinophils in blood and tissue serve as 
biomarkers.68,84- 87 Detection of granular protein deposits in 
tissues is helpful. A value exceeding 1.5 × 109/L that is unex-
plained by other diseases is regarded as HE, and when associ-
ated with organ damage or dysfunction in more than 2 organs 
is regarded as HES, or when associated with in one organ, as 
hypereosinophilic organ disease.88 Conventional therapy for 
HE and HES consists of anti- inflammatory treatment using 
systemic glucocorticoids, immunosuppressives and UVA- 1 
phototherapy,35,76,78,84 as well as by eradicating underlying 
conditions. Pharmacotherapy often does not lead to satisfac-
tory results, due to toxicity and lack of efficacy.
Clonal HE and clonal HES are treated with drugs act-
ing at specific molecular targets, for example, FIP1L1- 
PDGFRA (the most sensitive target of imatinib).39,83,89- 91 
For non- responders or in those developing acute leukaemia, 
conventional chemotherapy and hematopoietic stem cell 
transplantation have to be considered, while in irreversible 
endomyocardial fibrosis and related heart failure, heart trans-
plantation remains an option.92 Biologics with specificity 
for eosinophils, targeting IL- 5 and IL- 5R, such as mepoli-
zumab, reslizumab or benralizumab have shown promising 
effects.42,52,93
Alternative approaches for targeting type- 2 inflamma-
tion consist of substances affecting eosinophil chemotaxis, 
such as anti- eotaxin- 1 antibodies (bertilimumab), which 
have recently demonstrated promising results,53 as well as 
substances that block production of the transcription factor 
GATA- 3, by means of a GATA- 3 mRNA- specific antisense 
molecule, HgD40. HgD40 belongs to the class of DNAzymes, 
which are synthetic DNA molecules. HgD40 contains a cat-
alytic domain through which it exerts its cleavage function 
once sequence- specific domains bind to the GATA- 3 mRNA. 
Clinical efficacy of this treatment by inhalation has been 
shown following allergen provocation in mild and moderate 
asthmatic patients.94 Clinical responses are associated with a 
significant reduction of eosinophils in the sputum. These ob-
servations have been now extended to a subgroup of chronic 
obstructive pulmonary disease patients, characterized by the 
presence of at least 2% sputum eosinophils.95
5 |  CONCLUSIONS
Eosinophils are evolutionarily present from the early verte-
brates.96 They contribute to marked inflammation in tissues 
with both protective (eg against parasites) and pathogenic ef-
fects (eg hypereosinophilic conditions). In terms of general 
health effects, transgenic mouse models have shown that it 
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is possible to live without eosinophils, but that the organism 
is better off having them. Eosinophilic diseases manifest in 
various organs, most notably in the skin, the GI tract, the air-
ways, the heart, and with rare involvement of the nervous 
system and the vasculature. HES involves symptoms in vari-
ous organs, with a fusion gene mutation or reactive IL- 5 up- 
regulation. To manage hypereosinophilic conditions, history, 
physical examination, laboratory investigations, histology 
and imaging analyses are performed. Genetic analyses for 
mutations allow distinction between myeloid and lymphoid 
variants.
While systemic glucocorticoids remain the mainstay of 
treatment, particularly in the initial phase, prognosis has 
improved markedly through the introduction of targeted 
therapies implementing anti- IL- 5 antibodies and kinase in-
hibitors.43,97 Through a better understanding of eosinophil 
function in health and disease, and with the development 
of specific kinase inhibitors as well as targeted biologics, 
the era of precision medicine has now arrived in the field 
of eosinophilic diseases. Recent findings in transgenic mice 
and preliminary human studies targeting new receptors on 
eosinophils and blockade of transcription factors impart 
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